| Bioactivity | LXRβ agonist-4 is a potent, orally active Liver X receptors (LXRs) inhibitor with an IC50 value of 0.0078 μM for LXRβ. LXRβ agonist-4 inhibits RANKL-induced osteoclast differentiation and bone resorption. LXRβ agonist-4 can be used in research of osteoporosis[1]. |
| Target | IC50: 0.0078 μM (LXRβ) |
| Invitro | LXRβ agonist-4 (compound B9; 0.03-10 μM) 抑制 RANKL 诱导的破骨细胞生成和骨吸收[1]。LXRβ agonist-4 (1 μM; 0-24 h) 调节破骨细胞相关基因表达和 LXR 下游[1]。 Western Blot Analysis[1] Cell Line: |
| In Vivo | LXRβ agonist-4 (compound B9; 10 mg/kg; i.g.) 抑制去卵巢的雌性 C57BL/6 小鼠的骨质流失[1]。 Animal Model: |
| Name | LXRβ agonist-4 |
| Formula | C31H31FN2O7S |
| Molar Mass | 594.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chen H, et, al. Discovery of Spiro[pyrrolidine-3,3'-oxindole] LXRβ Agonists for the Treatment of Osteoporosis. J Med Chem. 2023 Jan 12;66(1):752-765. |